Compare TTEC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEC | ALDX |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | 69400 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 101.1M |
| IPO Year | 1996 | 2014 |
| Metric | TTEC | ALDX |
|---|---|---|
| Price | $2.46 | $1.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 459.0K | ★ 960.2K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.80 | 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,509,171,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $1.98 | $1.07 |
| 52 Week High | $5.59 | $6.18 |
| Indicator | TTEC | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 34.72 |
| Support Level | $2.12 | $1.48 |
| Resistance Level | $2.66 | $1.88 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 16.00 | 13.51 |
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.